ASH 2017 | Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies
Immune checkpoint inhibitors and T-cell engaging bi-specific antibodies have shown promising activity against lymphoid malignancies. In this interview, Anthony Mato, MD, MSCE, of the University of Pennsylvania, Philadelphia, PA, discusses the open-label, multicenter study of REGN2810 alone or in combination with REGN1979 in patients with B-lymphoid malignancies (NCT02651662). This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Get great new content delivered to your inboxSign up